Longeveron (LGVN) Return on Capital Employed (2023 - 2026)
Longeveron (LGVN) posted quarterly Return on Capital Employed of 200.88% for Q1 2026, down 11488.0% year-over-year from N/an in Q1 2025, and up 23.9% quarter-over-quarter from 263.97% in Q4 2025.
Longeveron (LGVN) Return on Capital Employed (2023 - 2026) Analysis & Trends
Longeveron's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 200.88% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 11488.0% year-over-year to 200.88%; the TTM figure through Mar 2026 stood at 200.88% (down 11488.0% YoY), while the FY2025 annual figure was 168.47%, down 6671.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 200.88%, up from 263.97% in the prior quarter.
- The five-year high for Return on Capital Employed was 65.68% in Q4 2024, with the low at 364.83% in Q1 2024.
- The 4-year median for Return on Capital Employed is 160.49% (2024), against an average of 171.48%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 27268 bps in 2024, then soared 27883 bps in 2025.
- Longeveron's Return on Capital Employed stood at 264.1% in 2023, then jumped by 75 bps to 65.68% in 2024, then sank by 302 bps to 263.97% in 2025, then gained by 24 bps to 200.88% in 2026.
- Business Quant data shows LGVN's Return on Capital Employed at 200.88% in Q1 2026, 263.97% in Q4 2025, and 197.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -168.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -168.46% |
| Mar 31, 2026 | -200.88% |
| Dec 31, 2025 | -263.97% |
| Sep 30, 2025 | -197.71% |
| Jun 30, 2025 | -125.74% |
| Mar 31, 2025 | -86.00% |
| Dec 31, 2024 | -65.68% |
| Sep 30, 2024 | -82.03% |
| Jun 30, 2024 | -160.49% |
| Mar 31, 2024 | -364.83% |
| Dec 31, 2023 | -264.10% |
| Sep 30, 2023 | -189.97% |
| Jun 30, 2023 | -135.71% |
| Mar 31, 2023 | -92.15% |